Premium
ASXL1 mutations in primary and secondary myelofibrosis
Author(s) -
Ricci Clara,
Spinelli Orietta,
Salmoiraghi Silvia,
Finazzi Guido,
Carobbio Alessandra,
Rambaldi Alessandro
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.08865.x
Subject(s) - myelofibrosis , primary (astronomy) , medicine , mutation , cancer research , genetics , biology , gene , bone marrow , physics , astronomy
Aivado, M., Schulte, K., Henze, L., Burger, J., Finke, J. & Haas, R. (2002) Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Seminars in Oncology, 29, 19–22. Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., Hoelzer, D., Mitrou, P.S. & Weidmann, E. (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87, 33–43. Friedberg, J.W. (2009) Bendamustine in chronic lymphocytic leukemia: the future is combination therapy. Leukaemia & Lymphoma, 50, 1399–1400. de Haij, S., Jansen, J.H., Boross, P., Beurskens, F.J., Bakema, J.E., Bos, D.L., Martens, A., Verbeek, J.S., Parren, P.W., van de Winkel, J.G. & Leusen, J.H. (2010) In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Research, 70, 3209–3217. Hallek, M. (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 1, 440–449. Iannitto, E., Morabito, F., Mancuso, S., Gentile, M., Montanini, A., Augello, A., Bongarzoni, V., D’Arco, A., Di Renzo, N., Fazzi, R., Franco, G., Marasca, R., Mule, A., Musso, M., Musto, P., Pennese, E., Piccin, A., Rota-Scalabrini, D., Visani, G. & Rigacci, L. (2010) Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. British Journal of Haematology, 153, 351–357. Lin, T.S. (2010) New agents in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 5, 29–34. Reagan, J.L. & Castillo, J.J. (2010) Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 11, 151–160. Tsimberidou, A.M. (2010) Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc), 46, 451–461. Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J.B., Yi, Q. & Wang, M. (2009) Synergistic antitumour effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American Journal of Hematology, 84, 553– 559.